## Review setup
- **Input scope** Abstract only
- **Assessment boundary** Claims and evidence presented in the abstract; no full text, figures, tables, or supplementary materials were provided
- **Shared manuscript claim summary** The authors use molecular dynamics simulations to investigate the YAP/TAZ-TEAD interaction, focusing on the role of TEAD autopalmitoylation at a conserved cysteine and the effects of a small-molecule palmitoylation inhibitor. They report atomistic insights into the dynamics of this interaction and claim that the inhibitor differentially affects YAP versus TAZ binding to TEAD, with implications for therapeutic design.
- **Visible evidence base** Abstract text only; no methodological details, simulation parameters, quantitative results, or structural analyses are available
- **Missing materials affecting confidence** Full manuscript, simulation protocols, force field parameters, system setup, convergence criteria, error analysis, structural figures, quantitative binding data, and any comparison with experimental results

## Reviewer
- **Overall assessment** The abstract addresses a biologically and clinically relevant question, namely the mechanistic basis of TEAD palmitoylation in YAP/TAZ binding and the mode of action of small-molecule inhibitors. The claim that the inhibitor differentially modulates YAP versus TAZ binding is potentially interesting, but the abstract provides no quantitative or methodological evidence to support this assertion. The mechanistic link between palmitoylation and binding affinity is stated as a gap in knowledge, yet the abstract does not explain how the simulations resolve this gap. The work may be of interest to computational biophysicists and cancer biologists, but the current evidence base is insufficient to evaluate technical soundness or the robustness of the conclusions.
- **Who would be interested in the results, and why** Computational biophysicists studying protein-protein interactions and allosteric regulation would be interested in the methodological approach. Cancer biologists and drug discovery researchers targeting the Hippo pathway would be interested in the potential differential effects of inhibitors on YAP versus TAZ, as this could inform therapeutic strategies. Structural biologists studying palmitoylation-dependent regulation of transcription factor complexes may also find the results relevant.
- **Major strengths** The biological question is well motivated and clinically significant. The focus on atomistic mechanisms of palmitoylation in a key oncogenic interaction is timely. The claim of differential inhibitor effects on YAP versus TAZ, if substantiated, would be a novel contribution.
- **Major Concerns** 
  - R1-M1
  - R1-M2
  - R1-M3
- **Minor Comments** 
  - R1-m1
  - R1-m2
  - R1-m3
- **Technical failings that need to be addressed before the case is established** R1-M1, R1-M2, R1-M3
- **Assessment against Nature-style criteria** Originality: The question of how palmitoylation modulates YAP/TAZ-TEAD binding is not entirely new, but the specific claim of differential inhibitor effects on YAP versus TAZ could be original if rigorously demonstrated. Scientific importance: High, given the role of the Hippo pathway in cancer. Interdisciplinary readership: The topic bridges biophysics, structural biology, and oncology, but the abstract does not currently make the work accessible to nonspecialists due to a lack of mechanistic detail. Technical soundness: Cannot be assessed from the abstract alone; no methodological or quantitative evidence is provided. Readability for nonspecialists: The abstract is clear in its biological framing but lacks the detail needed to evaluate the computational claims.
- **Recommendation posture** Currently not established from the provided evidence. The abstract presents a plausible hypothesis but does not provide sufficient evidence to support the central claims. A full manuscript with detailed methods and results would be required to assess whether the conclusions are justified.

### Major Concerns

- **Concern ID** R1-M1
- **Severity** Major
- **Blocking** Yes
- **Axis** Evidence
- **Claim pointer** The authors claim that molecular dynamics simulations provide "detailed atomistic insight into the YAP/TAZ-TEAD dynamics" and that the inhibitor "influences the binding of YAP and TAZ to TEAD in distinct manners."
- **Evidence pointer** Abstract only; location not provided
- **Concern** The abstract provides no quantitative data, such as binding free energies, residence times, or structural metrics, to support the claim of distinct inhibitor effects on YAP versus TAZ. No simulation details are given, including system size, force field, simulation length, or convergence criteria.
- **Why it matters** Without quantitative evidence and methodological transparency, the central claim of differential modulation cannot be evaluated. The distinction between YAP and TAZ binding is the key novel finding, and it must be supported by robust statistical and structural analysis.
- **Resolution test** Provide quantitative binding metrics with error estimates, show convergence of simulations, and include structural analyses that demonstrate the differential effect. Ideally, compare with experimental data on YAP and TAZ binding affinities.

- **Concern ID** R1-M2
- **Severity** Major
- **Blocking** Yes
- **Axis** Mechanistic link
- **Claim pointer** The authors state that "how exactly palmitoylation contributes to YAP/TAZ-TEAD interactions" remains unknown, implying that their simulations address this gap.
- **Evidence pointer** Abstract only; location not provided
- **Concern** The abstract does not explain how palmitoylation is modeled in the simulations, whether the palmitoylated and non-palmitoylated states are compared, or what specific mechanistic insight is derived. The link between palmitoylation and binding is asserted but not demonstrated.
- **Why it matters** The stated gap in knowledge is the motivation for the study, and the abstract must indicate how the simulations resolve this gap. Without a clear mechanistic explanation, the contribution is unclear.
- **Resolution test** Describe how palmitoylation is incorporated in the simulations, compare palmitoylated versus non-palmitoylated states, and identify specific structural or dynamic changes that explain the effect on YAP/TAZ binding.

- **Concern ID** R1-M3
- **Severity** Major
- **Blocking** Yes
- **Axis** Validation
- **Claim pointer** The authors imply that their findings have "significant implications for the design and deployment of future molecular interventions."
- **Evidence pointer** Abstract only; location not provided
- **Concern** No experimental validation or comparison with known experimental data is mentioned. The abstract does not state whether the simulations reproduce known binding affinities or inhibitor effects, nor whether any predictions are tested.
- **Why it matters** Computational predictions without experimental context or validation are difficult to interpret. The claim of therapeutic implications requires at least some connection to experimental observations or a clear predictive framework.
- **Resolution test** Compare simulation results with experimental binding data for YAP and TAZ, or with known inhibitor effects. If no experimental comparison is possible, state this limitation explicitly and temper the claims accordingly.

### Minor Comments

- **Concern ID** R1-m1
- **Severity** Minor
- **Axis** Clarity
- **Affected element** Abstract wording
- **Evidence pointer** Abstract, sentence on "distinct manners"
- **Issue** The phrase "influences the binding of YAP and TAZ to TEAD in distinct manners" is vague. It is unclear whether the difference is in affinity, kinetics, or binding mode.
- **Required correction** Specify the nature of the differential effect, such as a difference in binding free energy, residence time, or conformational preference.

- **Concern ID** R1-m2
- **Severity** Minor
- **Axis** Completeness
- **Affected element** Abstract scope
- **Evidence pointer** Abstract, final sentence
- **Issue** The abstract does not mention which specific small-molecule inhibitor was studied, nor its name or class.
- **Required correction** Identify the inhibitor studied and, if relevant, its known experimental properties.

- **Concern ID** R1-m3
- **Severity** Minor
- **Axis** Reproducibility
- **Affected element** Methods description
- **Evidence pointer** Abstract only; location not provided
- **Issue** No information is given on the simulation software, force field, or analysis methods, which are essential for reproducibility.
- **Required correction** Include key methodological details in the abstract or refer to a methods section in the full manuscript.

## Risk / unsupported claims
- The claim that the inhibitor differentially affects YAP and TAZ binding is unsupported by any quantitative evidence in the abstract.
- The claim of "detailed atomistic insight" is not substantiated without specific structural or dynamic findings.
- The implication of therapeutic significance is not supported by any experimental or translational evidence in the abstract.
- The mechanistic role of palmitoylation in YAP/TAZ-TEAD binding is asserted as a gap that the study addresses, but the abstract does not show how this gap is filled.